Provided by Tiger Trade Technology Pte. Ltd.

Septerna, Inc.

38.30
+0.33000.87%
Volume:26.74K
Turnover:1.01M
Market Cap:1.79B
PE:-70.61
High:38.42
Open:37.37
Low:36.89
Close:37.97
52wk High:51.10
52wk Low:13.67
Shares:46.68M
Float Shares:22.90M
Volume Ratio:0.60
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5424
EPS(LYR):-1.1044
ROE:-6.34%
ROA:-7.13%
PB:4.62
PE(LYR):-34.68

Loading ...

Wells Fargo Sticks to Their Buy Rating for Septerna, Inc. (SEPN)

TIPRANKS
·
20 hours ago

Septerna Files Initial Beneficial Ownership Statement for Chief Medical Officer Rajiv Patni

Reuters
·
Sep 04

Septerna SVP Drug Discovery Daniel D. Long Disposes of Common Shares Worth $126,081.52

Reuters
·
Sep 04

Septerna to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 01

Septerna (SEPN) Names A New CMO, Is The Upside Already Priced In?

Simply Wall St.
·
Aug 30

Is Septerna (SEPN) Elevating Its Clinical Strategy With a Veteran Regulatory Leader at the Helm?

Simply Wall St.
·
Aug 26

Press Release: Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Dow Jones
·
Aug 25

Septerna is Maintained at Overweight by JP Morgan

Dow Jones
·
Aug 20

Septerna price target raised to $48 from $38 at JPMorgan

TIPRANKS
·
Aug 19

U.S. Research Roundup-Cogent Communications, Dollar Tree, Home Depot

Reuters
·
Aug 19

Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 17

Truist Financial Reaffirms Their Buy Rating on Septerna, Inc. (SEPN)

TIPRANKS
·
Aug 14

Septerna President, COO Elizabeth Bhatt Sells 25,000 Shares Worth $1.1 Million Under 10b5-1 Plan

Reuters
·
Aug 14

Does Septerna (SEPN) Pair Narrowing Losses With A Cash Runway That Truly Supports Its Pipeline Strategy?

Simply Wall St.
·
Aug 13

Septerna, Inc. : Wells Fargo Raises Target Price to $50 from $48

THOMSON REUTERS
·
Aug 12

Wall Street Analysts Are Bullish on Top NA Picks

TIPRANKS
·
Aug 12

Septerna is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 11

Septerna price target raised to $49 from $45 at Raymond James

TIPRANKS
·
Aug 11

C4 Therapeutics Q2 Revenue Beats Estimates, Helped by Roche Collaboration

Reuters
·
Aug 11

Septerna Q2 Loss Narrows, Revenue Rises

MT Newswires Live
·
Aug 11